Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Adults With IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial
American Society of Nephrology (ASN) Kidney Week – 2024
Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Poster
Published on October 25, 2024
About the research
Summary
Background
- Sparsentan is a non-immunosuppressive, Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in adults with IgA nephropathy who are at risk for disease progression1-5
- It has demonstrated sustained proteinuria reduction and preservation of kidney function in the PROTECT study6
- In clinical studies, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have reduced proteinuria and the risk of progression to kidney failure in patients with IgA nephropathy7,8
- Previous clinical data from the PROTECT open-label extension (OLE) indicated that adding an SGLT2i to stable sparsentan was generally well tolerated and demonstrated a benefit on proteinuria reduction9
Aim
This analysis of the ongoing PROTECT OLE period evaluated the safety and efficacy of stable sparsentan with the addition of an SGLT2i in IgA nephropathy1
Approach
- All patients who completed the double-blind period and met the eligibility criteria were enrolled in the OLE period1
- This analysis will assess data from a subset of patients who chose to receive concomitant treatment during the PROTECT OLE period1
Key findings
- Adding an SGLT2i to stable sparsentan1:
- Demonstrated further reduction in proteinuria (urine protein-creatinine ratio [UPCR])
- Showed relatively stable body weight and blood pressure over time
- Adding an SGLT2i to stable sparsentan was generally well tolerated – no cases of Hy’s Law were reported1
Conclusions
- Findings from this analysis are consistent with the additive benefit on proteinuria reduction seen by adding an SGLT2i to stable sparsentan, and combination treatment was generally well tolerated1
- This suggests that sparsentan in combination with an SGLT2i as part of a broader treatment plan may be a consideration for patients with IgA nephropathy1
Related content
Footnotes
DEARA, Dual Endothelin Angiotensin Receptor Antagonist; IgA, immunoglobulin A; OLE, open-label extension; SGLT2i, sodium-glucose cotransporter-2 inhibitor; UPCR, urine protein-creatinine ratio.
- Kooienga I et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-PO851.
- Kohan DE et al. Clin Sci. 2024;138(11):645-662.
- FILSPARI® (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc.
- FILSPARI® (sparsentan) Summary of Product Characteristics. Paris, France: Vifor France.
- Trachtman H et al. Expert Rev Clin Immunol. 2024;20(6):571-576.
- Rovin BH et al. Lancet. 2023;402(10417):2077-2090.
- Wheeler DC et al. Kidney Int. 2021;100(1):215-224.
- EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-127.
- Kooienga I et al. Poster presented at: American Society of Nephrology Kidney Week 2023; November 2-5, 2023; Philadelphia, PA. SA-PO903.
MA-SP-24-0132 | October 2025